Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

NCT02606305 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Mirvetuximab soravtansine
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Pegylated Liposomal Doxorubicin
DRUG: Pembrolizumab

Sponsor

ImmunoGen, Inc.